Mn Services Vermogensbeheer B.V. boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 595.5% during the second quarter, Holdings Channel reports. The institutional investor owned 46,443 shares of the medical equipment provider’s stock after buying an additional 39,765 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Hologic were worth $2,108,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Swiss National Bank boosted its position in Hologic by 23.4% in the first quarter. Swiss National Bank now owns 1,028,124 shares of the medical equipment provider’s stock valued at $43,747,000 after buying an additional 195,100 shares in the last quarter. Earnest Partners LLC boosted its position in Hologic by 168,145.9% in the first quarter. Earnest Partners LLC now owns 205,260 shares of the medical equipment provider’s stock valued at $8,734,000 after buying an additional 205,138 shares in the last quarter. Lincoln Capital Corp purchased a new position in Hologic during the fourth quarter valued at approximately $377,000. KAMES CAPITAL plc purchased a new position in Hologic during the first quarter valued at approximately $718,000. Finally, LS Investment Advisors LLC boosted its position in Hologic by 10.9% in the first quarter. LS Investment Advisors LLC now owns 12,890 shares of the medical equipment provider’s stock valued at $548,000 after buying an additional 1,268 shares in the last quarter. 94.04% of the stock is currently owned by hedge funds and other institutional investors.

Hologic, Inc. (NASDAQ HOLX) opened at 45.28 on Thursday. Hologic, Inc. has a 1-year low of $35.15 and a 1-year high of $46.80. The stock has a market capitalization of $12.68 billion, a price-to-earnings ratio of 16.24 and a beta of 0.91. The company has a 50-day moving average of $45.02 and a 200-day moving average of $42.68.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.46 by $0.04. The firm had revenue of $715.40 million during the quarter, compared to analysts’ expectations of $685.24 million. Hologic had a net margin of 27.31% and a return on equity of 25.26%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.47 earnings per share. Analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2017/07/20/hologic-inc-nasdaqholx-stake-increased-by-mn-services-vermogensbeheer-b-v.html.

HOLX has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “strong-buy” rating and set a $49.00 price target for the company in a research note on Tuesday, April 4th. Leerink Swann restated an “outperform” rating and set a $52.00 price target on shares of Hologic in a research note on Thursday, March 30th. Canaccord Genuity restated a “buy” rating and set a $53.00 price target on shares of Hologic in a research note on Tuesday, May 9th. Barclays PLC set a $50.00 price target on shares of Hologic and gave the stock a “buy” rating in a research note on Wednesday, April 5th. Finally, BTIG Research restated a “buy” rating and set a $47.00 price target on shares of Hologic in a research note on Sunday, May 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $47.77.

In related news, Director Sally Crawford sold 16,969 shares of the firm’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $44.00, for a total transaction of $746,636.00. Following the completion of the transaction, the director now directly owns 157,305 shares of the company’s stock, valued at $6,921,420. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lawrence M. Levy sold 2,960 shares of the firm’s stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $44.54, for a total transaction of $131,838.40. Following the transaction, the director now directly owns 45,634 shares of the company’s stock, valued at $2,032,538.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 101,108 shares of company stock valued at $4,469,012. Corporate insiders own 0.79% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.